Predicting cost-benefits before programs are started: Looking at conjugate vaccine for invasive pneumococcal infections

Journal of Community Health

Volumn 25, Issue 1, 2000, Pages 23-33

  Hueston, William J ^a   Mainous III, Arch G ^a   Brauer, Nicole ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHILD; COST BENEFIT ANALYSIS; DRUG COST; HEALTH PROGRAM; HUMAN; INFANT; NEWBORN; NEWBORN INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTERIAL VACCINES; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION TREES; FORECASTING; HEALTH CARE COSTS; HUMANS; INCIDENCE; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; VACCINATION; VACCINES, CONJUGATE;

EID: 0034002750     PISSN: 00945145     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005136817158     Document Type: Article

References (20)

1. Pichichero ME, Shelly MA, Treanor JJ. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Ped Inf Dis J 1997;16:72-74.
2. Baltimore RS. New challenges in the development of a conjugate pneumococcal vaccine. JAMA 1992;268:3366-3367.
3. Centers for Disease Control and Prevention. Pneumococcal polysaccharide vaccine. MMWR 1989; 38:64-67, 68-77.
4. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-35.
5. Bluestone CD. Current therapy for otitis media and criteria for evaluation of new antimicrobial agents. Clin Infect Dis 1992;14 (Suppl 2):S197-S203.
6. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. The immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatrics 1996:128:649-53.
7. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-8):1-24.
8. Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994:271:375-81.
9. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B vaccine transmission by immunization. JAMA 1995:274:1201-8.
10. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention effectiveness. New York: Oxford University Press, 1996.
11. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention. JAMA 1996;275:194-98.
12. Kornelisse RF, Westerbeek CML, Spoor AB, van der Heijde B, Spanjaard L, Neijens HJ, de Groot R. Pneumococcal meningitis in children: Prognostic indicators and outcome. Clin Inf Dis 1995; 21:1390-7.
13. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Inf Dis 1981; 3:246-53.
14. Bol P. Epidemiology of bacterial meningitis in the Netherlands [thesis, vol 2]. Amsterdam: University of Amsterdam, 1987.
15. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a Meta-analysis. Ped Inf Dis J 1993;12:389-94.
16. Tengs TO, Adams ME, Pliskin JS, Safran DG, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-89.
17. Spika J, Facklam R, Plikaytis B, Oxtoby M. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991;163:1273-78.
18. Tuomanen EI, Astrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-84.
19. Broome CV, Facklam RR, Allen JR, Fraser DW, Austrian R. From the Centers for Disease Control and Prevention: Epidemiology of pneumococcal serotypes in the United States, 1978-1979. J Infect Dis 1980;141:119-23.
20. Centers for Disease Control and Prevention. Surveillance for penicillin-nonsusceptible Streptococcus pneumoniae - New York City, 1995. MMWR 1997;46:297-319.